GlassScriptPhysician profile
Joseph Doan
NPI 1528445210
$1,992.49
in general payments reported to CMS, 2019-2025
31 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2020: $210 · 2021: $321 · 2022: $141 · 2023: $392 · 2024: $267 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $383.48 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $231.06 | 2019-2024 | Jynarque |
| Alexion Pharmaceuticals, INC. | $132.78 | 2019-2024 | Ultomiris |
| Amgen INC. | $115.14 | 2020-2025 | Tavneos, Krystexxa |
| Travere Therapeutics, INC. | $102.69 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.80 | 2021-2023 | |
| Horizon Therapeutics Plc | $91.23 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $81.09 | 2021-2024 | Veltassa, Zemaira |
| Calliditas Therapeutics US INC. | $76.13 | 2023-2025 | Tarpeyo |
| Novo Nordisk INC | $55.76 | 2025 | Ozempic |
| Fresenius USA Marketing, INC. | $54.09 | 2022-2023 | |
| Genzyme Corporation | $53.35 | 2025 | |
| Tactile Systems Technology INC | $46.63 | 2021-2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.76 | 2023-2024 | Jardiance |
| Glaxosmithkline, LLC. | $40.84 | 2023 | Benlysta, Jesduvroq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $36.83 | 2021-2023 | |
| Outset Medical INC | $35.79 | 2025 | |
| Akebia Therapeutics INC | $30.88 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.83 | 2025 | |
| Eusa Pharma (US) LLC | $26.07 | 2022 | |
| Recordati_rare_diseases_inc. | $26.07 | 2022 | |
| Inspire Medical Systems, INC. | $24.62 | 2024 | Inspire |
| Electromed, INC. | $24.25 | 2025 | Smartvest |
| Abbott Laboratories | $24.13 | 2021 | |
| Renalytix Ai, INC. | $24.13 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Regeneron Healthcare Solutions, INC. | $22.16 | 2025 | Dupixent |
| Xeris Pharmaceuticals, INC. | $19.70 | 2025 | Keveyis |
| Veloxis Pharmaceuticals, INC. | $19.32 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.79 | 2023 | Gattex |
| Aurinia Pharma U.S., INC. | $17.41 | 2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Doan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.